Apply Demo
  • Home

    >>

  • News

    >>

  • Teva Pharma, Alvotech Announce FDA Approval For SELARSDI

News

We provide the latest news
from the world of economics and finance

05 May
Teva Pharma, Alvotech Announce FDA Approval For SELARSDI

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Alvotech (ALVO) announced the FDA has approved SELARSDI injection as interchangeable with the reference biologic Stelara or ustekinumab. As of April 30, 2025, SELARSDI is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohns disease, and ulcerative colitis.

In August 2020, Teva and Alvotech entered into a partnership for the commercialization of five Alvotech biosimilar product candidates, and in July 2023, the partnership was extended to include two additional biosimilars and new presentations of two previously partnered products. Alvotech manages development and manufacturing, while Teva is responsible for the exclusive commercialization in the U.S.

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2025 Lime Trading (CY) Ltd

Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520

Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus

Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details

Risk warning:

Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.

Tel: +357 25 055 966

E-mail: 24_support@j2t.com

visa
master card
union-pay
х
Risk warning: Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.